Interní Med. 2015; 17(5): 264-266

Pharmacotherapy after acute coronary syndrome: What is the right choice?

MUDr.Jan Přeček, doc.MUDr.Martin Hutyra, Ph.D.
I. interní klinika &ndash, kardiologická, Fakultní nemocnice Olomouc, Lékařská fakulta Univerzity Palackého v Olomouci

The article provides a brief summary of the basic pharmacotherapy recommended in patients following acute coronary syndrome.

Emphasis is mainly placed on antiplatelet therapy using the novel antiplatelet agents ticagrelor and prasugrel as well as on highdose

treatment with statins. Also discussed is the treatment with beta blockers and with drugs targeting the renin-angiotensinaldosterone

system.

Keywords: acute coronary syndrome, pharmacotherapy, antiplatelet therapy, statins

Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Přeček J, Hutyra M. Pharmacotherapy after acute coronary syndrome: What is the right choice? Interní Med. 2015;17(5):264-266.
Download citation

References

  1. Widimský P, Želízko M, Jánský P, et al (on behalf of the CZECH investigators). The incidence, treatment strategies and outcomes of acute coronary syndromes in the "reperfusion network" of different hospital types in the Czech republic: results of the Czech evaluation of acute coronary syndromes in hospitalized patients (CZECH) registry. Int J Cardiol 2007; 119: 212-219. Go to original source... Go to PubMed...
  2. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057. Go to original source... Go to PubMed...
  3. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients withacute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. Go to original source... Go to PubMed...
  4. Piťha J, Štulc T, Janota T, Hricák V. Léčba statiny u pacientů s akutním koronárním syndromem. Společné stanovisko České společnosti pro aterosklerózu, Pracovní skupiny akutní kardiologie České kardiologické společnosti a Pracovnej skupiny akútnej kardiológie Slovenskej kardiologickej spoločnosti. Interv Akut Kardiol 2012; 11(2): 89-90.
  5. Cannon CP, Blazing MA, Giugliano RP, et al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372: 2387-2397. Go to original source... Go to PubMed...
  6. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054. Go to original source... Go to PubMed...
  7. Ošťádal P. Komplexní péče o pacienta po inferktu myokardu. In: Táborský M, et al. Novinky v kardiologii 2015. Mladá fronta Praha 2015: 92-99.
  8. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33(20): 2569-2619; doi: 10.1093/eurheartj/ehs215. Epub 2012 Aug 24.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.